These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15080914)

  • 1. Potent and orally active ET(A) selective antagonists with 5,7-diarylcyclopenteno[1,2-b]pyridine-6-carboxylic acid structures.
    Yoshizumi T; Takahashi H; Ohtake N; Jona H; Sato Y; Kishino H; Sakamoto T; Ozaki S; Takahashi H; Shibata Y; Ishii Y; Saito M; Okada M; Hayama T; Nishikibe M
    Bioorg Med Chem; 2004 May; 12(9):2139-50. PubMed ID: 15080914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationships of a novel class of endothelin receptor selective antagonists; 6-carboxy-2-isopropylamino-5,7-diarylcyclopenteno[1,2-b]pyridines.
    Takahashi H; Ohtake N; Sakamoto T; Iino T; Kawanishi N; Nakamura M; Yoshizumi T; Niiyama K; Ozaki S; Okada H; Kano A; Takahashi H; Ishii Y; Okada M; Saito M; Sawazaki Y; Hayama T; Nishikibe M
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1503-7. PubMed ID: 15006391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and pharmacological activity of 1,3,6-trisubstituted-4-oxo-1,4-dihydroquinoline-2-carboxylic acids as selective ET(A) antagonists.
    Patel HJ; Olgun N; Lengyel I; Reznik S; Stephani RA
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6840-4. PubMed ID: 20932745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Activity relationships of 2-substituted 5,7-Diarylcyclopenteno[1,2-b]pyridine-6-carboxylic acids as a novel class of endothelin receptor antagonists.
    Niiyama K; Takahashi H; Nagase T; Kojima H; Amano Y; Katsuki K; Yamakawa T; Ozaki S; Ihara M; Yano M; Fukuroda T; Nishikibe M; Ishikawa K
    Bioorg Med Chem Lett; 2002 Nov; 12(21):3041-5. PubMed ID: 12372497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides, and sulfonylureas as novel antagonists of the CXCR2 receptor.
    Winters MP; Crysler C; Subasinghe N; Ryan D; Leong L; Zhao S; Donatelli R; Yurkow E; Mazzulla M; Boczon L; Manthey CL; Molloy C; Raymond H; Murray L; McAlonan L; Tomczuk B
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1926-30. PubMed ID: 18308567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722.
    Winn M; von Geldern TW; Opgenorth TJ; Jae HS; Tasker AS; Boyd SA; Kester JA; Mantei RA; Bal R; Sorensen BK; Wu-Wong JR; Chiou WJ; Dixon DB; Novosad EI; Hernandez L; Marsh KC
    J Med Chem; 1996 Mar; 39(5):1039-48. PubMed ID: 8676339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and activity of a series of pyrrolidine-3-carboxylic acid-based, highly specific, orally active ET(B) antagonists containing a diphenylmethylamine acetamide side chain.
    Liu G; Kozmina NS; Winn M; von Geldern TW; Chiou WJ; Dixon DB; Nguyen B; Marsh KC; Opgenorth TJ
    J Med Chem; 1999 Sep; 42(18):3679-89. PubMed ID: 10479299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.
    Wu C; Decker ER; Blok N; Bui H; You TJ; Wang J; Bourgoyne AR; Knowles V; Berens KL; Holland GW; Brock TA; Dixon RA
    J Med Chem; 2004 Apr; 47(8):1969-86. PubMed ID: 15055997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.
    Bolli MH; Marfurt J; Grisostomi C; Boss C; Binkert C; Hess P; Treiber A; Thorin E; Morrison K; Buchmann S; Bur D; Ramuz H; Clozel M; Fischli W; Weller T
    J Med Chem; 2004 May; 47(11):2776-95. PubMed ID: 15139756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P450 2C8 (CYP2C8)-mediated hydroxylation of an endothelin ETA receptor antagonist in human liver microsomes.
    Ma B; Subramanian R; Schrag ML; Rodrigues AD; Tang C
    Drug Metab Dispos; 2004 May; 32(5):473-8. PubMed ID: 15100167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist.
    Murugesan N; Gu Z; Spergel S; Young M; Chen P; Mathur A; Leith L; Hermsmeier M; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Koplowitz B; Humphreys WG; Chong S; Morrison RA; Webb ML; Moreland S; Trippodo N; Barrish JC
    J Med Chem; 2003 Jan; 46(1):125-37. PubMed ID: 12502366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists.
    Jae HS; Winn M; Dixon DB; Marsh KC; Nguyen B; Opgenorth TJ; von Geldern TW
    J Med Chem; 1997 Sep; 40(20):3217-27. PubMed ID: 9379441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent and orally bioavailable non-peptide antagonists at the human bradykinin B(1) receptor based on a 2-alkylamino-5-sulfamoylbenzamide core.
    Ritchie TJ; Dziadulewicz EK; Culshaw AJ; Müller W; Burgess GM; Bloomfield GC; Drake GS; Dunstan AR; Beattie D; Hughes GA; Ganju P; McIntyre P; Bevan SJ; Davis C; Yaqoob M
    J Med Chem; 2004 Sep; 47(19):4642-4. PubMed ID: 15341478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
    Patt WC; Edmunds JJ; Repine JT; Berryman KA; Reisdorph BR; Lee C; Plummer MS; Shahripour A; Haleen SJ; Keiser JA; Flynn MA; Welch KM; Reynolds EE; Rubin R; Tobias B; Hallak H; Doherty AM
    J Med Chem; 1997 Mar; 40(7):1063-74. PubMed ID: 9089328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity.
    Smith ND; Poon SF; Huang D; Green M; King C; Tehrani L; Roppe JR; Chung J; Chapman DP; Cramer M; Cosford ND
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5481-4. PubMed ID: 15482908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 6-Carboxy-5,7-diarylcyclopenteno[1,2-b]pyridine derivatives: a novel class of endothelin receptor antagonists.
    Niiyama K; Mase T; Takahashi H; Naya A; Katsuki K; Nagase T; Ito S; Hayama T; Hisaka A; Ozaki S; Ihara M; Yano M; Fukuroda T; Noguchi K; Nishikibe M; Ishikawa K
    Bioorg Med Chem; 2002 Aug; 10(8):2461-70. PubMed ID: 12057635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further optimization of sulfonamide analogs as EP1 receptor antagonists: synthesis and evaluation of bioisosteres for the carboxylic acid group.
    Naganawa A; Matsui T; Ima M; Saito T; Murota M; Aratani Y; Kijima H; Yamamoto H; Maruyama T; Ohuchida S; Nakai H; Toda M
    Bioorg Med Chem; 2006 Nov; 14(21):7121-37. PubMed ID: 16879970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2C8- and CYP3A-mediated C-demethylation of (3-{[(4-tert-butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (CP-533,536), an EP2 receptor-selective prostaglandin E2 agonist: characterization of metabolites by high-resolution liquid chromatography-tandem mass spectrometry and liquid chromatography/mass spectrometry-nuclear magnetic resonance.
    Prakash C; Wang W; O'Connell T; Johnson KA
    Drug Metab Dispos; 2008 Oct; 36(10):2093-103. PubMed ID: 18653741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of endothelin ETB receptor system aggravates neointimal hyperplasia after balloon injury of rat carotid artery.
    Kitada K; Yui N; Matsumoto C; Mori T; Ohkita M; Matsumura Y
    J Pharmacol Exp Ther; 2009 Dec; 331(3):998-1004. PubMed ID: 19737855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.